28. 全身性アミロイドーシス Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
124I-AT03
Attralus, Inc.
2021 Phase 1 NCT05201911 United States;
124I-labeled monoclonal antibody Mu 11-1F4
University of Tennessee
2008 Phase 1 NCT01409148 United States;
2008 Phase 1 NCT00807872 United States;
124I-p5+14 Injection
University of Tennessee Graduate School of Medicine
2018 Phase 1/Phase 2 NCT03678259 United States;
2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
John L. Berk
2010 - EUCTR2006-001066-16-GB Italy;Sweden;United Kingdom;
John L. Berk, M.D.
2007 - EUCTR2006-001066-16-SE Italy;Sweden;United Kingdom;
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat
FoldRx Pharmaceuticals, Inc.
2007 Phase 2;Phase 3 EUCTR2006-002792-41-GB Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Ltd.
2009 - EUCTR2009-011535-12-FR France;Germany;Italy;Portugal;Sweden;
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate
FoldRx Pharmaceuticals Limited
2009 - EUCTR2008-001262-87-DE France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-SE France;Germany;Portugal;Sweden;
2007 - EUCTR2006-002792-41-DE Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-SE Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Inc.
2008 Phase 2;Phase 3 EUCTR2008-001262-87-FR France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-PT France;Germany;Portugal;Sweden;
2006 - EUCTR2006-002792-41-PT Germany;Portugal;Spain;Sweden;United Kingdom;
26866138
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc
2020 Phase 3 EUCTR2018-004670-10-IT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
Eidos Therapeutics, Inc.
2020 Phase 3 EUCTR2018-004670-10-PT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-HU Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-FR Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-DE Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-BG Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
- Phase 3 EUCTR2018-004670-10-NL Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey;
4'-iodo-4'-deoxydoxorubicin
National Cancer Institute (NCI)
2001 Phase 1 NCT00030381 United States;
1999 Phase 2 NCT00003853 Italy;United States;
A single booster dose of the Moderna mRNA COVID-19 vaccine
Barbara Ann Karmanos Cancer Institute
2021 Phase 2 NCT05028374 United States;
A01AC02
E.M.N. - EUROPEAN MYELOMA NETWORK
2013 Phase 3 EUCTR2010-022395-31-CZ Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States;
AG10
Eidos Therapeutics, a BridgeBio company
2020 Phase 3 NCT04418024 Canada;Spain;United States;
AG10 HCl
Eidos Therapeutics, Inc
2020 Phase 3 EUCTR2018-004670-10-IT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
Eidos Therapeutics, Inc.
2020 Phase 3 EUCTR2018-004670-10-PT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-HU Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-FR Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-DE Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-BG Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
- Phase 3 EUCTR2018-004670-10-NL Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey;
AL
Caelum Medical Monitor
2021 Phase 3 JPRN-jRCT2031200300 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russia;Spain;UK;US;
2021 Phase 3 JPRN-jRCT2031200299 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russia;Spain;UK;US;
ALN-51547
Alnylam Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2015-005333-49-GB Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-SE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-ES Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-DE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-BE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2014-003835-20-GB Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
ALN-TTRSC
ALNYLAM PHARMACEUTICALS, INC.
2015 Phase 3 EUCTR2014-003835-20-IT Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2015-005333-49-GB Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-SE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-ES Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-DE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-BE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2014-003835-20-GB Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
Aciclin
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Acoramidis
Eidos Therapeutics
2021 Phase 3 NCT04882735 -
Acyclovir
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
Alkeran
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
European Myeloma Network
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
2012 - EUCTR2010-022395-31-GR Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Allogeneic hematopoietic stem cell transplantation
Fred Hutchinson Cancer Research Center
2000 - NCT00014235 Germany;Italy;United States;
Amifostine trihydrate
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
Anakinra
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2006-001927-20-IT Italy;
Antiviral therapy
City of Hope Medical Center
2010 - NCT01199562 United States;
Aprotinin
National Center for Global Health and Medicine
2013 - JPRN-UMIN000012319 Japan;
Autologous bone marrow transplantation
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Autologous hematopoietic stem cell transplantation
Mayo Clinic
2005 Phase 3 NCT00477971 United States;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Autologous hematopoietic stem cell transplantation (ASCT)
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
Autologous peripheral blood stem cell transplantation
Boston Medical Center
2000 Phase 2 NCT00075621 United States;
Autologous stem cell transplant
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Autologous stem cell transplantation
Boston Medical Center
2001 Phase 2 NCT00075608 United States;
University Hospital, Limoges
2000 Phase 3 NCT00344526 France;
Autologous-autologous tandem hematopoietic stem cell transplantation
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
BMDex
European Myeloma Network
2011 Phase 3 NCT01277016 Italy;
Belantamab mafodotin
European Myeloma Network
2021 Phase 2 NCT04617925 France;Germany;Greece;Italy;Netherlands;United Kingdom;
European Myeloma Network – EMN
2021 Phase 2 EUCTR2020-004001-32-NL France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-GR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-FR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-DE France;Germany;Greece;Italy;Netherlands;United Kingdom;
STICHTING EUROPEAN MYELOMA NETWORK
2021 Phase 2 EUCTR2020-004001-32-IT France;Germany;Greece;Italy;Netherlands;United Kingdom;
Belantamab mafodotin 1.9 mg/kg (8 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 2.5 mg/kg (4 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 2.5 mg/kg (6 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 2.5 mg/kg (8 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Bendamustine
Columbia University
2013 Phase 2 NCT01222260 United States;
Betamethasone
E.M.N. - EUROPEAN MYELOMA NETWORK
2012 - EUCTR2010-022395-31-ES Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Birtamimab
Prothena Biosciences Ltd.
2021 Phase 3 NCT04973137 Australia;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Bone Marrow Aspiration and Biopsy
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
Bone marrow ablation with stem cell support
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Bortezomib
Barbara Ann Karmanos Cancer Institute
2013 Phase 1 NCT01728259 Canada;New Zealand;United States;
2007 Phase 2 NCT00520767 United States;
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
2009 Phase 2 NCT01083316 United States;
2008 Phase 2 NCT00790647 United States;
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-022395-31-IT Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;
Emory University
2021 Phase 1 NCT04754945 United States;
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
JANSSEN-CILAG
2005 - EUCTR2004-004871-12-IT Italy;
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
Mayo Clinic
2018 Phase 2 NCT03130348 United States;
2010 Phase 2 NCT01072773 United States;
Memorial Sloan Kettering Cancer Center
2007 Phase 2 NCT00458822 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
National Cancer Institute (NCI)
2010 Phase 3 NCT01078454 United States;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
University College London
2010 - EUCTR2009-014906-33-GB United Kingdom;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Zhi-Hong Liu, M.D.
2011 - NCT01273844 China;
Bortezomib Accord
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Bortezomib D-mannitol
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Memorial Sloan Kettering Cancer Center
2011 - NCT01383759 United States;
Busulfan
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
CAEL-101
Caelum Biosciences
2020 Phase 2 NCT04304144 United States;
Caelum Biosciences, Inc.
2021 Phase 3 EUCTR2020-000713-32-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000713-32-BE Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-FR Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-BE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 NCT04512235 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 NCT04504825 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GB Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
CC-4047
OSPEDALE POLICLINICO S. MATTEO
2012 - EUCTR2011-001787-22-IT Italy;
CC-5013
Mayo Clinic
2005 Phase 2 NCT00166413 United States;
CETIRIZINA DICLORIDRATO
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
CHIMERIC FIBRIL-REACTIVE IGG1K MONOCLONAL ANTIBODY 11-1F4
Caelum Biosciences, Inc.
2021 Phase 3 EUCTR2020-000713-32-BE Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-FR Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GB Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
CHX A-DTPA anti-CD66 antibody
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
CHX-A-DTPA-Anti-CD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
CPHC (carboxy pyrrolidine hexanoyl pyrrolidone carboxylate)
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
Carboplatin
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Carfilzomib
University College, London
2015 Phase 1/Phase 2 NCT02545907 United Kingdom;
Carmustine
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Ch11-1F4 (NSC-711516)
Caelum Biosciences, Inc.
2021 Phase 3 EUCTR2020-000713-32-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-BE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Chemotherapy
IRCCS Policlinico S. Matteo
2015 Phase 2 NCT01531751 Italy;
Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Andrew Eisenberger
2014 Phase 1 NCT02245867 United States;
Cisplatin
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Current treatment of AL-CM
Second Affiliated Hospital, School of Medicine, Zhejiang University
2021 - NCT04924998 China;
Cyclophosphamide
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
Emory University
2021 Phase 1 NCT04754945 United States;
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
Guangdong Provincial People's Hospital
2020 Phase 4 NCT04612582 China;
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
IRCCS Policlinico S. Matteo
2008 Phase 2 NCT00607581 Italy;
Icahn School of Medicine at Mount Sinai
2017 Phase 1/Phase 2 NCT03236792 United States;
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Mayo Clinic
2010 Phase 2 NCT01072773 United States;
2007 Phase 2 NCT00564889 United States;
OSPEDALE POLICLINICO S. MATTEO
2008 - EUCTR2007-006037-13-IT Italy;
PETHEMA Foundation
2010 Phase 2 NCT01194791 Spain;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab
Janssen Pharmaceutical K.K.
2018 Phase 3 JPRN-JapicCTI-183929 Japan, Asia except Japan, North America, Europe;
Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)
Caelum Biosciences
2020 Phase 2 NCT04304144 United States;
Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Caelum Biosciences, Inc.
2020 Phase 3 NCT04504825 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Caelum Biosciences, Inc.
2020 Phase 3 NCT04512235 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Cyclosporine
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
Pfizer Inc.
2009 - EUCTR2009-011535-12-DE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
Pfizer Inc.
2009 - EUCTR2009-011535-12-PT Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
DAZARLEX
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
DESAMETASONE
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
DEXAMETHASONE SODIUM SULFATE
OSPEDALE POLICLINICO S. MATTEO
2012 - EUCTR2011-001787-22-IT Italy;
DNA analysis
City of Hope Medical Center
2010 - NCT01199562 United States;
Daratumumab
Boston Medical Center
2017 Phase 1/Phase 2 NCT02841033 United States;
CHU DE LIMOGES
2017 Phase 2 EUCTR2016-000287-42-IT France;Italy;
Caelum Biosciences
2020 Phase 2 NCT04304144 United States;
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
M.D. Anderson Cancer Center
2018 Phase 1 NCT03283917 United States;
University Hospital, Limoges
2016 Phase 2 NCT02816476 France;Italy;
Weill Medical College of Cornell University
2021 Phase 2 NCT04270175 United States;
Daratumumab and pomalidomide
IRCCS Policlinico S. Matteo
2021 Phase 2 NCT04895917 Italy;
Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20)
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-SE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-PL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-NL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-HU Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GR Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GB Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-ES Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DK Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-BE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Daratumumab coformulato con ialuronidasi umana ricombinante (rHuPH20)
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2016-001737-27-IT Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Darzalex
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
Deaxamethasone
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
Decadron
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
Dexametasone
E.M.N. - EUROPEAN MYELOMA NETWORK
2012 - EUCTR2010-022395-31-ES Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Dexamethason
European Myeloma Network
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
Dexamethasone
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
2013 Phase 1 NCT01728259 Canada;New Zealand;United States;
2007 Phase 2 NCT00520767 United States;
Boston Medical Center
2012 Phase 1/Phase 2 NCT01570387 United States;
2009 Phase 2 NCT01083316 United States;
2008 Phase 2 NCT00679367 United States;
Columbia University
2013 Phase 2 NCT01222260 United States;
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
2011 - EUCTR2010-022395-31-SE Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-022395-31-IT Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;
Emory University
2021 Phase 1 NCT04754945 United States;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
HOVON Foundation
2012 Phase 3 EUCTR2010-021445-42-DE Belgium;Germany;Netherlands;
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
IRCCS Policlinico S. Matteo
2008 Phase 2 NCT00607581 Italy;
Icahn School of Medicine at Mount Sinai
2017 Phase 1/Phase 2 NCT03236792 United States;
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
M.D. Anderson Cancer Center
2018 Phase 1 NCT03283917 United States;
2014 Phase 1 NCT01807286 United States;
Mayo Clinic
2018 Phase 2 NCT03130348 United States;
2010 Phase 2 NCT01072773 United States;
2007 Phase 2 NCT00564889 United States;
2005 Phase 3 NCT00477971 United States;
Memorial Sloan Kettering Cancer Center
2018 Phase 2 NCT03618537 United States;
2007 Phase 2 NCT00458822 United States;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
2010 Phase 3 NCT01078454 United States;
OSPEDALE POLICLINICO S. MATTEO
2008 - EUCTR2007-006037-13-IT Italy;
Oncopeptides AB
2020 Phase 1/Phase 2 NCT04115956 Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
PETHEMA Foundation
2010 Phase 2 NCT01194791 Spain;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
1996 Phase 2 NCT00002849 United States;
Stanford University
2009 - NCT00890552 United States;
Tufts Medical Center
2017 Phase 1 NCT03000660 United States;
University College, London
2015 Phase 1/Phase 2 NCT02545907 United Kingdom;
University Hospital, Limoges
2000 Phase 3 NCT00344526 France;
Vaishali Sanchorawala
2004 Phase 2 NCT00091260 United States;
Weill Medical College of Cornell University
2022 Early Phase 1 NCT04984330 United States;
2021 Phase 2 NCT04270175 United States;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Dexamethasone 4 mg JENAPHARM
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Oncopeptides AB
2020 Phase 2 EUCTR2018-002761-19-DE Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2 EUCTR2018-002761-19-ES Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-PL Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-NO Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-GR Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-CZ Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Dexamethasone,
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Dexaton
European Myeloma Network
2012 - EUCTR2010-022395-31-GR Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
Dezamizumab
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
Diflunisal
Boston University
2006 Phase 2/Phase 3 NCT00294671 Italy;Japan;Portugal;Sweden;United Kingdom;United States;
Department of Neurology, Faculty of Life Sciences, Kumamoto University
2012 Phase 3 JPRN-UMIN000008396 Japan;
Shinshu University
2009 - JPRN-UMIN000001825 Japan;
Diflunisal (dolobid)
John L. Berk
2010 - EUCTR2006-001066-16-GB Italy;Sweden;United Kingdom;
John L. Berk, M.D.
2007 - EUCTR2006-001066-16-SE Italy;Sweden;United Kingdom;
Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)
IRCCS Policlinico S. Matteo
2012 Phase 2 NCT01511263 Italy;
Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
IRCCS Policlinico S. Matteo
2012 Phase 2 NCT01511263 Italy;
Dolobid
Boston University- The Amyloid Treatment and Research Program
2007 - EUCTR2006-001066-16-IT Italy;Sweden;United Kingdom;
Donor lymphocytes
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
Doxorubicin
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
DoxyHEXAL® tabs 100 mg Tabletten
Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo
2019 Phase 2;Phase 3 EUCTR2017-002210-31-DE Canada;Germany;Turkey;
Doxycycline
IRCCS Policlinico S. Matteo
2019 Phase 2/Phase 3 NCT03474458 Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom;
Medical College of Wisconsin
2014 Phase 2 NCT02207556 United States;
Elotuzumab
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
Enbrel
The Cleveland Clinic
2001 Phase 2 NCT00224393 -
Endoxan
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
Epigallocatechin-3-gallate (EGCG)
Florian Michel
2013 Phase 2 NCT02015312 Germany;
Eplontersen
Ionis Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2019-001698-10-SE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-DE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
Etoposide
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
FORTECORTIN
E.M.N. - EUROPEAN MYELOMA NETWORK
2013 Phase 3 EUCTR2010-022395-31-CZ Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States;
Filgrastim
Boston Medical Center
2008 Phase 2 NCT00790647 United States;
2001 Phase 2 NCT00075608 United States;
2000 Phase 2 NCT00075621 United States;
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Mayo Clinic
2005 Phase 3 NCT00477971 United States;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Fludarabine phosphate
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
Fortecortin
European Myeloma Network
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
HOVON Foundation
2012 Phase 3 EUCTR2010-021445-42-DE Belgium;Germany;Netherlands;
Foscarnet sodium
City of Hope Medical Center
2010 - NCT01199562 United States;
Fx-1006A
FOLDRX PHARMACEUTICALS, INC.
2010 - EUCTR2009-011535-12-IT France;Germany;Italy;Portugal;Sweden;
2008 - EUCTR2007-006791-12-IT France;Germany;Italy;
FoldRx Pharmaceuticals Limited
2009 - EUCTR2008-001262-87-DE France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-SE France;Germany;Portugal;Sweden;
2007 - EUCTR2006-002792-41-DE Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-SE Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Inc.
2008 Phase 2;Phase 3 EUCTR2008-001262-87-FR France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-PT France;Germany;Portugal;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-002792-41-GB Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-PT Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Ltd.
2009 - EUCTR2009-011535-12-FR France;Germany;Italy;Portugal;Sweden;
Pfizer
2008 Phase 2/Phase 3 NCT00791492 Argentina;Brazil;France;Germany;Portugal;Sweden;
2007 Phase 2/Phase 3 NCT00409175 Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States;
Pfizer Inc.
2009 - EUCTR2009-011535-12-PT Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
2009 - EUCTR2009-011535-12-DE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
GSK2315698
GlaxoSmithKline
2013 Phase 1 NCT01777243 United Kingdom;
2011 Phase 1 NCT01406314 United Kingdom;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
GSK2398852
GlaxoSmithKline
2013 Phase 1 NCT01777243 United Kingdom;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
GSK2857916
European Myeloma Network – EMN
2021 Phase 2 EUCTR2020-004001-32-NL France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-GR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-FR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-DE France;Germany;Greece;Italy;Netherlands;United Kingdom;
STICHTING EUROPEAN MYELOMA NETWORK
2021 Phase 2 EUCTR2020-004001-32-IT France;Germany;Greece;Italy;Netherlands;United Kingdom;
GSK3039294
GlaxoSmithKline
2016 Phase 1 NCT02603172 United Kingdom;
Ganciclovir
City of Hope Medical Center
2010 - NCT01199562 United States;
Green Tea Extract
Japanese Red Cross Medical Center, Division of Hematology
2015 Phase 2 JPRN-UMIN000019732 Japan;
H02AB02
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Oncopeptides AB
2020 Phase 2 EUCTR2018-002761-19-DE Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2 EUCTR2018-002761-19-ES Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-PL Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-NO Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-GR Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-CZ Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
H02AB02 Desametasone
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
HUMAX-CD38
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2016-001737-27-IT Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Janssen-Cilag International N.V.
2018 Phase 3 EUCTR2016-001737-27-SE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-PL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-NL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-HU Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GR Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GB Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-ES Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DK Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-BE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
High Cut-off Hemodialysis
IRCCS Policlinico S. Matteo
2015 Phase 2 NCT01531751 Italy;
HuMax-CD38
CHU DE LIMOGES
2017 Phase 2 EUCTR2016-000287-42-IT France;Italy;
CHU de Limoges
2016 Phase 2 EUCTR2016-000287-42-FR France;
HuMax-CD38, 3003-005
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
Human Transthyretin Antisense Oligonucleotide
Ionis Pharmaceuticals, Inc
2015 Phase 3 EUCTR2013-004561-13-GB Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004561-13-DE Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Ionis Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-005115-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005115-13-ES Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-PT Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-GB Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-DE Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-GB Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-FR Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc
2015 - EUCTR2013-004561-13-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-FR Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc.
2015 - EUCTR2012-001831-30-BG Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2012-001831-30-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-IT Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Humanized IgG1 kappa antiamyloid
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-NL Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-PT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-PL Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-HU Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-GR Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-ES Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-DK Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-DE Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2017 Phase 2 EUCTR2016-000489-50-IT Italy;
Prothena Therapeutics Limited
2018 Phase 2 EUCTR2016-004664-18-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GR Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-ES Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-ES Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
I124-AT01 only
Attralus, Inc.
2021 Phase 2 NCT05235269 United States;
ION-682884
Ionis Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001698-10-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-SE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GR Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-DE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-CY Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
IONIS-TTR Rx
Ionis Pharmaceuticals, Inc.
2014 Phase 3 NCT02175004 Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
ISIS 420915
Ionis Pharmaceuticals, Inc
2015 Phase 3 EUCTR2013-004561-13-GB Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004561-13-DE Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Ionis Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001698-10-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-SE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GR Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-DE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-CY Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2018 Phase 3 EUCTR2017-005115-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005115-13-ES Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-PT Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-GB Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-DE Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-GB Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-FR Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc
2015 - EUCTR2013-004561-13-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-FR Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc.
2015 - EUCTR2012-001831-30-BG Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2012-001831-30-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-IT Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Ibrutinib
Mayo Clinic
2018 Phase 2 NCT03130348 United States;
Imatinib mesylate
National Cancer Institute (NCI)
2001 Phase 1 NCT00025415 United States;
Imnovid
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2021 Phase 2 EUCTR2019-001962-13-IT Italy;
Indium 111-radiolabelled anti-CD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
Indium 111 labelled Anti-CD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
Infection prophylaxis and management
City of Hope Medical Center
2010 - NCT01199562 United States;
Inoserten
Ionis Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2019-001698-10-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
Inotersen
Ionis Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-005115-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2/Phase 3 NCT01737398 Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-GB Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-FR Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Isatuximab
Emory University
2021 Phase 1 NCT04754945 United States;
Southwest Oncology Group
2018 Phase 2 NCT03499808 United States;
Isis 420915/GSK 299872
Brigham and Women's Hospital
2016 Phase 2 NCT02627820 -
Ixazomib
Icahn School of Medicine at Mount Sinai
2017 Phase 1/Phase 2 NCT03236792 United States;
M.D. Anderson Cancer Center
2018 Phase 1 NCT03283917 United States;
Memorial Sloan Kettering Cancer Center
2018 Phase 2 NCT03618537 United States;
Ixazomib Citrate
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
JNJ-54767414
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
JnJ 54767414
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2016-001737-27-IT Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Janssen-Cilag International N.V.
2018 Phase 3 EUCTR2016-001737-27-SE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-PL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-NL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-HU Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GR Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GB Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-ES Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DK Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-BE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
KINERET*SC 7SIR 100MG 0,67ML
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2006-001927-20-IT Italy;
L01AA03
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)
Marianna Fontana
2021 - NCT04856267 United Kingdom;
Lenalidomide
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
Boston Medical Center
2008 Phase 2 NCT00679367 United States;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Heidelberg University
2009 Phase 2 NCT00883623 Germany;
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
IRCCS Policlinico S. Matteo
2008 Phase 2 NCT00607581 Italy;
Mayo Clinic
2007 Phase 2 NCT00564889 United States;
PETHEMA Foundation
2010 Phase 2 NCT01194791 Spain;
Seoul National University Hospital
2019 Phase 3 NCT04298372 Korea, Republic of;
Stanford University
2009 - NCT00890552 United States;
Vaishali Sanchorawala
2004 Phase 2 NCT00091260 United States;
Lenalidomide, Dexamethasone and Cyclophosphamide
University of Athens
2008 Phase 1/Phase 2 NCT00981708 Greece;
Lenogastrim
Joint UCLH and UCL Biomedical Research Unit
2007 Phase 2;Phase 3 EUCTR2006-006395-37-GB United Kingdom;
Management of therapy complications
City of Hope Medical Center
2010 - NCT01199562 United States;
Melflufen
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Melphalan
Barbara Ann Karmanos Cancer Institute
2007 Phase 2 NCT00520767 United States;
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
2009 Phase 2 NCT01083316 United States;
2008 Phase 2 NCT00790647 United States;
2008 Phase 2 NCT00679367 United States;
2001 Phase 2 NCT00075608 United States;
2000 Phase 2 NCT00075621 United States;
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
2011 - EUCTR2010-022395-31-SE Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-022395-31-IT Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
M.D. Anderson Cancer Center
2014 Phase 1 NCT01807286 United States;
Mayo Clinic
2005 Phase 3 NCT00477971 United States;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
National Cancer Institute (NCI)
2010 Phase 3 NCT01078454 United States;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Stanford University
2009 - NCT00890552 United States;
University Hospital, Limoges
2000 Phase 3 NCT00344526 France;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Melphalan fulfenamide hydrochloride
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Oncopeptides AB
2020 Phase 2 EUCTR2018-002761-19-DE Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2 EUCTR2018-002761-19-ES Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-PL Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-NO Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-GR Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-CZ Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Melphalan, thalidomide and dexamethasone
FDA Office of Orphan Products Development
2002 Phase 2 NCT01527032 -
Melphalan-Flufenamide (Melflufen)
Oncopeptides AB
2020 Phase 1/Phase 2 NCT04115956 Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Miridesap
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
Mycophenolate mofetil
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium
FoldRx Pharmaceuticals Limited
2009 - EUCTR2008-001262-87-DE France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-SE France;Germany;Portugal;Sweden;
2007 - EUCTR2006-002792-41-DE Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-SE Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Inc.
2008 Phase 2;Phase 3 EUCTR2008-001262-87-FR France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-PT France;Germany;Portugal;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-002792-41-GB Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-PT Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Ltd.
2009 - EUCTR2009-011535-12-FR France;Germany;Italy;Portugal;Sweden;
NEOD001
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2017 Phase 2 EUCTR2016-000489-50-IT Italy;
Prothena Therapeutics Limited
2018 Phase 2 EUCTR2016-004664-18-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GR Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-ES Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-ES Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
Prothena Therapeutics Ltd.
2017 Phase 2 NCT03154047 Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 NCT02632786 Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 NCT02613182 United States;
2015 Phase 3 NCT02312206 Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
NTLA-2001
Intellia Therapeutics
2020 Phase 1 NCT04601051 New Zealand;Sweden;United Kingdom;
Neupogen
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
Oral drops solution
E.M.N. - EUROPEAN MYELOMA NETWORK
2012 - EUCTR2010-022395-31-ES Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
PEGYLATED RECOMBINANT HUMAN HYALURONIDASE PH20
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
PF-06291826-83/Fx-1006A
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Paracetamolo Zentiva Italia
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Peripheral blood stem cell transplantation
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Pomalidomide
Barbara Ann Karmanos Cancer Institute
2013 Phase 1 NCT01728259 Canada;New Zealand;United States;
Boston Medical Center
2012 Phase 1/Phase 2 NCT01570387 United States;
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2021 Phase 2 EUCTR2019-001962-13-IT Italy;
M.D. Anderson Cancer Center
2014 Phase 1 NCT01807286 United States;
OSPEDALE POLICLINICO S. MATTEO
2012 - EUCTR2011-001787-22-IT Italy;
Weill Medical College of Cornell University
2021 Phase 2 NCT04270175 United States;
Pomalidomide and Dexamethasone
IRCCS Policlinico S. Matteo
2012 Phase 2 NCT01510613 Italy;
Propylene Glycol-Free Melphalan Hydrochloride
Boston Medical Center
2018 Phase 2 NCT02994784 United States;
Psyllium
Centre Hospitalier Universitaire de Nice
2021 - NCT04695340 France;
Quality-of-life assessment
Barbara Ann Karmanos Cancer Institute
2007 Phase 2 NCT00520767 United States;
RNA analysis
City of Hope Medical Center
2010 - NCT01199562 United States;
Recombinant interferon alfa
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Southwest Oncology Group
1996 Phase 2 NCT00002849 United States;
Revlimid
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
OSPEDALE POLICLINICO S. MATTEO
2008 - EUCTR2007-006037-13-IT Italy;
Revusiran
Alnylam Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2015-005333-49-GB Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-SE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-DE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-BE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2014-003835-20-GB Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
SOM0226
SOM Biotech SL
2014 Phase 1/Phase 2 NCT02191826 Spain;
STI-6129
Sorrento Therapeutics, Inc.
2021 Phase 1 NCT04316442 United States;
Sargramostim
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Selinexor
Weill Medical College of Cornell University
2022 Early Phase 1 NCT04984330 United States;
Siltuximab
Memorial Sloan Kettering Cancer Center
2017 Phase 2 NCT03315026 United States;
Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
University of Tennessee
2008 Phase 1 NCT01815086 United States;
Standard of care therapy
IRCCS Policlinico S. Matteo
2019 Phase 2/Phase 3 NCT03474458 Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom;
Stem Cell Collection
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
Stem Cell Infusion
Boston Medical Center
2008 Phase 2 NCT00790647 United States;
Stem cell infusion
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
2001 Phase 2 NCT00075608 United States;
Sunitinib malate
National Cancer Institute (NCI)
2009 Phase 1 NCT00890747 United States;
Tafamidis
Pfizer
2011 Phase 3 NCT01435655 Japan;
Tafamidis Meglumine 20mg Soft Gelatin Capsule (Clinical trial image)
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Tafamidis Meglumine 20mg Soft Gelatin Capsule (Commerical image)
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Tafamidis meglumine
Pfizer Inc.
2009 - EUCTR2009-011535-12-PT Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
2009 - EUCTR2009-011535-12-DE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Pfizer Japan Inc.
2011 Phase 3 JPRN-JapicCTI-111678 -
Tafamidis meglumine 20 mg soft gelatin capsules
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Tasmar
SOM Innovation Biotech SL (SOM Biotech)
2014 - EUCTR2014-001586-27-ES Spain;
Thalidomide
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
Guangdong Provincial People's Hospital
2020 Phase 4 NCT04612582 China;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
University College, London
2015 Phase 1/Phase 2 NCT02545907 United Kingdom;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Thiotepa
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
VELCADE*1FL 3,
JANSSEN-CILAG
2005 - EUCTR2004-004871-12-IT Italy;
Valganciclovir
City of Hope Medical Center
2010 - NCT01199562 United States;
Velcade
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
HOVON Foundation
2012 Phase 3 EUCTR2010-021445-42-DE Belgium;Germany;Netherlands;
2012 Phase 2 EUCTR2010-021445-42-BE Belgium;Germany;Netherlands;
2011 Phase 2 EUCTR2010-021445-42-NL Belgium;Germany;Netherlands;
University College London
2010 - EUCTR2009-014906-33-GB United Kingdom;
Venetoclax
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
Tufts Medical Center
2017 Phase 1 NCT03000660 United States;
Vyndaqel 20mg soft capsule
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Yttrium-90 radiolabelled anti-CD66 antibody
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
Yttrium90 radiolabelled antiCD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
ZN-d5
K-Group Alpha, Inc.
2021 Phase 1/Phase 2 NCT05199337 United States;
Zirtec
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
[18F]Florbetaben
IRCCS Policlinico S. Matteo
2020 - NCT04392960 Italy;
[18F]florbetaben
Life Molecular Imaging GmbH
2022 Phase 3 NCT05184088 -
microarray analysis
Barbara Ann Karmanos Cancer Institute
2007 Phase 2 NCT00520767 United States;
polymerase chain reaction
City of Hope Medical Center
2010 - NCT01199562 United States;
protein expression analysis
City of Hope Medical Center
2010 - NCT01199562 United States;
Attralus, Inc.
2021 Phase 1 NCT05201911 United States;
124I-labeled monoclonal antibody Mu 11-1F4
University of Tennessee
2008 Phase 1 NCT01409148 United States;
2008 Phase 1 NCT00807872 United States;
124I-p5+14 Injection
University of Tennessee Graduate School of Medicine
2018 Phase 1/Phase 2 NCT03678259 United States;
2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
John L. Berk
2010 - EUCTR2006-001066-16-GB Italy;Sweden;United Kingdom;
John L. Berk, M.D.
2007 - EUCTR2006-001066-16-SE Italy;Sweden;United Kingdom;
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat
FoldRx Pharmaceuticals, Inc.
2007 Phase 2;Phase 3 EUCTR2006-002792-41-GB Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Ltd.
2009 - EUCTR2009-011535-12-FR France;Germany;Italy;Portugal;Sweden;
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate
FoldRx Pharmaceuticals Limited
2009 - EUCTR2008-001262-87-DE France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-SE France;Germany;Portugal;Sweden;
2007 - EUCTR2006-002792-41-DE Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-SE Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Inc.
2008 Phase 2;Phase 3 EUCTR2008-001262-87-FR France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-PT France;Germany;Portugal;Sweden;
2006 - EUCTR2006-002792-41-PT Germany;Portugal;Spain;Sweden;United Kingdom;
26866138
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc
2020 Phase 3 EUCTR2018-004670-10-IT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
Eidos Therapeutics, Inc.
2020 Phase 3 EUCTR2018-004670-10-PT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-HU Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-FR Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-DE Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-BG Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
- Phase 3 EUCTR2018-004670-10-NL Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey;
4'-iodo-4'-deoxydoxorubicin
National Cancer Institute (NCI)
2001 Phase 1 NCT00030381 United States;
1999 Phase 2 NCT00003853 Italy;United States;
A single booster dose of the Moderna mRNA COVID-19 vaccine
Barbara Ann Karmanos Cancer Institute
2021 Phase 2 NCT05028374 United States;
A01AC02
E.M.N. - EUROPEAN MYELOMA NETWORK
2013 Phase 3 EUCTR2010-022395-31-CZ Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States;
AG10
Eidos Therapeutics, a BridgeBio company
2020 Phase 3 NCT04418024 Canada;Spain;United States;
AG10 HCl
Eidos Therapeutics, Inc
2020 Phase 3 EUCTR2018-004670-10-IT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
Eidos Therapeutics, Inc.
2020 Phase 3 EUCTR2018-004670-10-PT Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-HU Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-FR Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-DE Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
2020 Phase 3 EUCTR2018-004670-10-BG Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey;
- Phase 3 EUCTR2018-004670-10-NL Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey;
AL
Caelum Medical Monitor
2021 Phase 3 JPRN-jRCT2031200300 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russia;Spain;UK;US;
2021 Phase 3 JPRN-jRCT2031200299 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russia;Spain;UK;US;
ALN-51547
Alnylam Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2015-005333-49-GB Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-SE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-ES Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-DE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-BE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2014-003835-20-GB Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
ALN-TTRSC
ALNYLAM PHARMACEUTICALS, INC.
2015 Phase 3 EUCTR2014-003835-20-IT Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2015-005333-49-GB Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-SE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-ES Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-DE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-BE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2014-003835-20-GB Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
Aciclin
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Acoramidis
Eidos Therapeutics
2021 Phase 3 NCT04882735 -
Acyclovir
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
Alkeran
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
European Myeloma Network
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
2012 - EUCTR2010-022395-31-GR Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Allogeneic hematopoietic stem cell transplantation
Fred Hutchinson Cancer Research Center
2000 - NCT00014235 Germany;Italy;United States;
Amifostine trihydrate
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
Anakinra
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2006-001927-20-IT Italy;
Antiviral therapy
City of Hope Medical Center
2010 - NCT01199562 United States;
Aprotinin
National Center for Global Health and Medicine
2013 - JPRN-UMIN000012319 Japan;
Autologous bone marrow transplantation
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Autologous hematopoietic stem cell transplantation
Mayo Clinic
2005 Phase 3 NCT00477971 United States;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Autologous hematopoietic stem cell transplantation (ASCT)
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
Autologous peripheral blood stem cell transplantation
Boston Medical Center
2000 Phase 2 NCT00075621 United States;
Autologous stem cell transplant
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Autologous stem cell transplantation
Boston Medical Center
2001 Phase 2 NCT00075608 United States;
University Hospital, Limoges
2000 Phase 3 NCT00344526 France;
Autologous-autologous tandem hematopoietic stem cell transplantation
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
BMDex
European Myeloma Network
2011 Phase 3 NCT01277016 Italy;
Belantamab mafodotin
European Myeloma Network
2021 Phase 2 NCT04617925 France;Germany;Greece;Italy;Netherlands;United Kingdom;
European Myeloma Network – EMN
2021 Phase 2 EUCTR2020-004001-32-NL France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-GR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-FR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-DE France;Germany;Greece;Italy;Netherlands;United Kingdom;
STICHTING EUROPEAN MYELOMA NETWORK
2021 Phase 2 EUCTR2020-004001-32-IT France;Germany;Greece;Italy;Netherlands;United Kingdom;
Belantamab mafodotin 1.9 mg/kg (8 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 2.5 mg/kg (4 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 2.5 mg/kg (6 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Belantamab mafodotin 2.5 mg/kg (8 weeks)
University of Texas Southwestern Medical Center
2022 Phase 1/Phase 2 NCT05145816 United States;
Bendamustine
Columbia University
2013 Phase 2 NCT01222260 United States;
Betamethasone
E.M.N. - EUROPEAN MYELOMA NETWORK
2012 - EUCTR2010-022395-31-ES Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Birtamimab
Prothena Biosciences Ltd.
2021 Phase 3 NCT04973137 Australia;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Bone Marrow Aspiration and Biopsy
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
Bone marrow ablation with stem cell support
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Bortezomib
Barbara Ann Karmanos Cancer Institute
2013 Phase 1 NCT01728259 Canada;New Zealand;United States;
2007 Phase 2 NCT00520767 United States;
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
2009 Phase 2 NCT01083316 United States;
2008 Phase 2 NCT00790647 United States;
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-022395-31-IT Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;
Emory University
2021 Phase 1 NCT04754945 United States;
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
JANSSEN-CILAG
2005 - EUCTR2004-004871-12-IT Italy;
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
Mayo Clinic
2018 Phase 2 NCT03130348 United States;
2010 Phase 2 NCT01072773 United States;
Memorial Sloan Kettering Cancer Center
2007 Phase 2 NCT00458822 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
National Cancer Institute (NCI)
2010 Phase 3 NCT01078454 United States;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
University College London
2010 - EUCTR2009-014906-33-GB United Kingdom;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Zhi-Hong Liu, M.D.
2011 - NCT01273844 China;
Bortezomib Accord
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Bortezomib D-mannitol
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Memorial Sloan Kettering Cancer Center
2011 - NCT01383759 United States;
Busulfan
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
CAEL-101
Caelum Biosciences
2020 Phase 2 NCT04304144 United States;
Caelum Biosciences, Inc.
2021 Phase 3 EUCTR2020-000713-32-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000713-32-BE Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-FR Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-BE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 NCT04512235 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 NCT04504825 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GB Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
CC-4047
OSPEDALE POLICLINICO S. MATTEO
2012 - EUCTR2011-001787-22-IT Italy;
CC-5013
Mayo Clinic
2005 Phase 2 NCT00166413 United States;
CETIRIZINA DICLORIDRATO
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
CHIMERIC FIBRIL-REACTIVE IGG1K MONOCLONAL ANTIBODY 11-1F4
Caelum Biosciences, Inc.
2021 Phase 3 EUCTR2020-000713-32-BE Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-FR Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GB Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
CHX A-DTPA anti-CD66 antibody
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
CHX-A-DTPA-Anti-CD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
CPHC (carboxy pyrrolidine hexanoyl pyrrolidone carboxylate)
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
Carboplatin
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Carfilzomib
University College, London
2015 Phase 1/Phase 2 NCT02545907 United Kingdom;
Carmustine
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Ch11-1F4 (NSC-711516)
Caelum Biosciences, Inc.
2021 Phase 3 EUCTR2020-000713-32-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-PL Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004254-28-BE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2020-000713-32-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-GR Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004254-28-DE Australia;Austria;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Chemotherapy
IRCCS Policlinico S. Matteo
2015 Phase 2 NCT01531751 Italy;
Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Andrew Eisenberger
2014 Phase 1 NCT02245867 United States;
Cisplatin
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Current treatment of AL-CM
Second Affiliated Hospital, School of Medicine, Zhejiang University
2021 - NCT04924998 China;
Cyclophosphamide
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
Emory University
2021 Phase 1 NCT04754945 United States;
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
Guangdong Provincial People's Hospital
2020 Phase 4 NCT04612582 China;
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
IRCCS Policlinico S. Matteo
2008 Phase 2 NCT00607581 Italy;
Icahn School of Medicine at Mount Sinai
2017 Phase 1/Phase 2 NCT03236792 United States;
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Mayo Clinic
2010 Phase 2 NCT01072773 United States;
2007 Phase 2 NCT00564889 United States;
OSPEDALE POLICLINICO S. MATTEO
2008 - EUCTR2007-006037-13-IT Italy;
PETHEMA Foundation
2010 Phase 2 NCT01194791 Spain;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab
Janssen Pharmaceutical K.K.
2018 Phase 3 JPRN-JapicCTI-183929 Japan, Asia except Japan, North America, Europe;
Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)
Caelum Biosciences
2020 Phase 2 NCT04304144 United States;
Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Caelum Biosciences, Inc.
2020 Phase 3 NCT04504825 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Caelum Biosciences, Inc.
2020 Phase 3 NCT04512235 Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Cyclosporine
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
Pfizer Inc.
2009 - EUCTR2009-011535-12-DE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
Pfizer Inc.
2009 - EUCTR2009-011535-12-PT Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
DAZARLEX
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
DESAMETASONE
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
DEXAMETHASONE SODIUM SULFATE
OSPEDALE POLICLINICO S. MATTEO
2012 - EUCTR2011-001787-22-IT Italy;
DNA analysis
City of Hope Medical Center
2010 - NCT01199562 United States;
Daratumumab
Boston Medical Center
2017 Phase 1/Phase 2 NCT02841033 United States;
CHU DE LIMOGES
2017 Phase 2 EUCTR2016-000287-42-IT France;Italy;
Caelum Biosciences
2020 Phase 2 NCT04304144 United States;
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
M.D. Anderson Cancer Center
2018 Phase 1 NCT03283917 United States;
University Hospital, Limoges
2016 Phase 2 NCT02816476 France;Italy;
Weill Medical College of Cornell University
2021 Phase 2 NCT04270175 United States;
Daratumumab and pomalidomide
IRCCS Policlinico S. Matteo
2021 Phase 2 NCT04895917 Italy;
Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20)
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-SE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-PL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-NL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-HU Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GR Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GB Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-ES Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DK Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-BE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Daratumumab coformulato con ialuronidasi umana ricombinante (rHuPH20)
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2016-001737-27-IT Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Darzalex
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
Deaxamethasone
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
Decadron
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
Dexametasone
E.M.N. - EUROPEAN MYELOMA NETWORK
2012 - EUCTR2010-022395-31-ES Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Dexamethason
European Myeloma Network
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
Dexamethasone
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
2013 Phase 1 NCT01728259 Canada;New Zealand;United States;
2007 Phase 2 NCT00520767 United States;
Boston Medical Center
2012 Phase 1/Phase 2 NCT01570387 United States;
2009 Phase 2 NCT01083316 United States;
2008 Phase 2 NCT00679367 United States;
Columbia University
2013 Phase 2 NCT01222260 United States;
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
2011 - EUCTR2010-022395-31-SE Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-022395-31-IT Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;
Emory University
2021 Phase 1 NCT04754945 United States;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
HOVON Foundation
2012 Phase 3 EUCTR2010-021445-42-DE Belgium;Germany;Netherlands;
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
IRCCS Policlinico S. Matteo
2008 Phase 2 NCT00607581 Italy;
Icahn School of Medicine at Mount Sinai
2017 Phase 1/Phase 2 NCT03236792 United States;
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
M.D. Anderson Cancer Center
2018 Phase 1 NCT03283917 United States;
2014 Phase 1 NCT01807286 United States;
Mayo Clinic
2018 Phase 2 NCT03130348 United States;
2010 Phase 2 NCT01072773 United States;
2007 Phase 2 NCT00564889 United States;
2005 Phase 3 NCT00477971 United States;
Memorial Sloan Kettering Cancer Center
2018 Phase 2 NCT03618537 United States;
2007 Phase 2 NCT00458822 United States;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
2010 Phase 3 NCT01078454 United States;
OSPEDALE POLICLINICO S. MATTEO
2008 - EUCTR2007-006037-13-IT Italy;
Oncopeptides AB
2020 Phase 1/Phase 2 NCT04115956 Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
PETHEMA Foundation
2010 Phase 2 NCT01194791 Spain;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
1996 Phase 2 NCT00002849 United States;
Stanford University
2009 - NCT00890552 United States;
Tufts Medical Center
2017 Phase 1 NCT03000660 United States;
University College, London
2015 Phase 1/Phase 2 NCT02545907 United Kingdom;
University Hospital, Limoges
2000 Phase 3 NCT00344526 France;
Vaishali Sanchorawala
2004 Phase 2 NCT00091260 United States;
Weill Medical College of Cornell University
2022 Early Phase 1 NCT04984330 United States;
2021 Phase 2 NCT04270175 United States;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Dexamethasone 4 mg JENAPHARM
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Oncopeptides AB
2020 Phase 2 EUCTR2018-002761-19-DE Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2 EUCTR2018-002761-19-ES Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-PL Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-NO Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-GR Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-CZ Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Dexamethasone,
Janssen Research & Development, LLC
2017 Phase 3 NCT03201965 Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Dexaton
European Myeloma Network
2012 - EUCTR2010-022395-31-GR Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
Dezamizumab
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
Diflunisal
Boston University
2006 Phase 2/Phase 3 NCT00294671 Italy;Japan;Portugal;Sweden;United Kingdom;United States;
Department of Neurology, Faculty of Life Sciences, Kumamoto University
2012 Phase 3 JPRN-UMIN000008396 Japan;
Shinshu University
2009 - JPRN-UMIN000001825 Japan;
Diflunisal (dolobid)
John L. Berk
2010 - EUCTR2006-001066-16-GB Italy;Sweden;United Kingdom;
John L. Berk, M.D.
2007 - EUCTR2006-001066-16-SE Italy;Sweden;United Kingdom;
Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)
IRCCS Policlinico S. Matteo
2012 Phase 2 NCT01511263 Italy;
Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
IRCCS Policlinico S. Matteo
2012 Phase 2 NCT01511263 Italy;
Dolobid
Boston University- The Amyloid Treatment and Research Program
2007 - EUCTR2006-001066-16-IT Italy;Sweden;United Kingdom;
Donor lymphocytes
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
Doxorubicin
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
DoxyHEXAL® tabs 100 mg Tabletten
Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo
2019 Phase 2;Phase 3 EUCTR2017-002210-31-DE Canada;Germany;Turkey;
Doxycycline
IRCCS Policlinico S. Matteo
2019 Phase 2/Phase 3 NCT03474458 Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom;
Medical College of Wisconsin
2014 Phase 2 NCT02207556 United States;
Elotuzumab
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
Enbrel
The Cleveland Clinic
2001 Phase 2 NCT00224393 -
Endoxan
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
Epigallocatechin-3-gallate (EGCG)
Florian Michel
2013 Phase 2 NCT02015312 Germany;
Eplontersen
Ionis Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2019-001698-10-SE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-DE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
Etoposide
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
FORTECORTIN
E.M.N. - EUROPEAN MYELOMA NETWORK
2013 Phase 3 EUCTR2010-022395-31-CZ Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States;
Filgrastim
Boston Medical Center
2008 Phase 2 NCT00790647 United States;
2001 Phase 2 NCT00075608 United States;
2000 Phase 2 NCT00075621 United States;
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Mayo Clinic
2005 Phase 3 NCT00477971 United States;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Fludarabine phosphate
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
Fortecortin
European Myeloma Network
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
HOVON Foundation
2012 Phase 3 EUCTR2010-021445-42-DE Belgium;Germany;Netherlands;
Foscarnet sodium
City of Hope Medical Center
2010 - NCT01199562 United States;
Fx-1006A
FOLDRX PHARMACEUTICALS, INC.
2010 - EUCTR2009-011535-12-IT France;Germany;Italy;Portugal;Sweden;
2008 - EUCTR2007-006791-12-IT France;Germany;Italy;
FoldRx Pharmaceuticals Limited
2009 - EUCTR2008-001262-87-DE France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-SE France;Germany;Portugal;Sweden;
2007 - EUCTR2006-002792-41-DE Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-SE Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Inc.
2008 Phase 2;Phase 3 EUCTR2008-001262-87-FR France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-PT France;Germany;Portugal;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-002792-41-GB Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-PT Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Ltd.
2009 - EUCTR2009-011535-12-FR France;Germany;Italy;Portugal;Sweden;
Pfizer
2008 Phase 2/Phase 3 NCT00791492 Argentina;Brazil;France;Germany;Portugal;Sweden;
2007 Phase 2/Phase 3 NCT00409175 Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States;
Pfizer Inc.
2009 - EUCTR2009-011535-12-PT Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
2009 - EUCTR2009-011535-12-DE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
GSK2315698
GlaxoSmithKline
2013 Phase 1 NCT01777243 United Kingdom;
2011 Phase 1 NCT01406314 United Kingdom;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
GSK2398852
GlaxoSmithKline
2013 Phase 1 NCT01777243 United Kingdom;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
GSK2857916
European Myeloma Network – EMN
2021 Phase 2 EUCTR2020-004001-32-NL France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-GR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-FR France;Germany;Greece;Italy;Netherlands;United Kingdom;
2021 Phase 2 EUCTR2020-004001-32-DE France;Germany;Greece;Italy;Netherlands;United Kingdom;
STICHTING EUROPEAN MYELOMA NETWORK
2021 Phase 2 EUCTR2020-004001-32-IT France;Germany;Greece;Italy;Netherlands;United Kingdom;
GSK3039294
GlaxoSmithKline
2016 Phase 1 NCT02603172 United Kingdom;
Ganciclovir
City of Hope Medical Center
2010 - NCT01199562 United States;
Green Tea Extract
Japanese Red Cross Medical Center, Division of Hematology
2015 Phase 2 JPRN-UMIN000019732 Japan;
H02AB02
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Oncopeptides AB
2020 Phase 2 EUCTR2018-002761-19-DE Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2 EUCTR2018-002761-19-ES Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-PL Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-NO Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-GR Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-CZ Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
H02AB02 Desametasone
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
HUMAX-CD38
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2016-001737-27-IT Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Janssen-Cilag International N.V.
2018 Phase 3 EUCTR2016-001737-27-SE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-PL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-NL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-HU Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GR Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GB Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-ES Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DK Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-BE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
High Cut-off Hemodialysis
IRCCS Policlinico S. Matteo
2015 Phase 2 NCT01531751 Italy;
HuMax-CD38
CHU DE LIMOGES
2017 Phase 2 EUCTR2016-000287-42-IT France;Italy;
CHU de Limoges
2016 Phase 2 EUCTR2016-000287-42-FR France;
HuMax-CD38, 3003-005
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
Human Transthyretin Antisense Oligonucleotide
Ionis Pharmaceuticals, Inc
2015 Phase 3 EUCTR2013-004561-13-GB Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004561-13-DE Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Ionis Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-005115-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005115-13-ES Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-PT Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-GB Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-DE Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-GB Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-FR Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc
2015 - EUCTR2013-004561-13-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-FR Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc.
2015 - EUCTR2012-001831-30-BG Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2012-001831-30-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-IT Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Humanized IgG1 kappa antiamyloid
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-NL Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-PT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-PL Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-HU Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-GR Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-ES Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-DK Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000037-14-DE Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2017 Phase 2 EUCTR2016-000489-50-IT Italy;
Prothena Therapeutics Limited
2018 Phase 2 EUCTR2016-004664-18-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GR Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-ES Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-ES Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
I124-AT01 only
Attralus, Inc.
2021 Phase 2 NCT05235269 United States;
ION-682884
Ionis Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001698-10-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-SE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GR Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-DE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-CY Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
IONIS-TTR Rx
Ionis Pharmaceuticals, Inc.
2014 Phase 3 NCT02175004 Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
ISIS 420915
Ionis Pharmaceuticals, Inc
2015 Phase 3 EUCTR2013-004561-13-GB Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004561-13-DE Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Ionis Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001698-10-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-SE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GR Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-DE Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;
2020 Phase 3 EUCTR2019-001698-10-CY Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;
2018 Phase 3 EUCTR2017-005115-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005115-13-ES Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-PT Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-GB Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-DE Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-GB Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-FR Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc
2015 - EUCTR2013-004561-13-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004561-13-FR Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Isis Pharmaceuticals, Inc.
2015 - EUCTR2012-001831-30-BG Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2012-001831-30-ES Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2012-001831-30-IT Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;
Ibrutinib
Mayo Clinic
2018 Phase 2 NCT03130348 United States;
Imatinib mesylate
National Cancer Institute (NCI)
2001 Phase 1 NCT00025415 United States;
Imnovid
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2021 Phase 2 EUCTR2019-001962-13-IT Italy;
Indium 111-radiolabelled anti-CD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
Indium 111 labelled Anti-CD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
Infection prophylaxis and management
City of Hope Medical Center
2010 - NCT01199562 United States;
Inoserten
Ionis Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2019-001698-10-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
Inotersen
Ionis Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-005115-13-PT Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
2013 Phase 2/Phase 3 NCT01737398 Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-GB Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-005115-13-FR Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;
Isatuximab
Emory University
2021 Phase 1 NCT04754945 United States;
Southwest Oncology Group
2018 Phase 2 NCT03499808 United States;
Isis 420915/GSK 299872
Brigham and Women's Hospital
2016 Phase 2 NCT02627820 -
Ixazomib
Icahn School of Medicine at Mount Sinai
2017 Phase 1/Phase 2 NCT03236792 United States;
M.D. Anderson Cancer Center
2018 Phase 1 NCT03283917 United States;
Memorial Sloan Kettering Cancer Center
2018 Phase 2 NCT03618537 United States;
Ixazomib Citrate
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
JNJ-54767414
European Myeloma Network
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
Janssen-Cilag International N.V.
2022 Phase 2 EUCTR2021-002639-48-ES Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States;
JnJ 54767414
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2016-001737-27-IT Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
Janssen-Cilag International N.V.
2018 Phase 3 EUCTR2016-001737-27-SE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-PL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-NL Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-HU Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GR Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-GB Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-ES Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DK Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-DE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001737-27-BE Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States;
KINERET*SC 7SIR 100MG 0,67ML
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2006-001927-20-IT Italy;
L01AA03
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)
Marianna Fontana
2021 - NCT04856267 United Kingdom;
Lenalidomide
Barbara Ann Karmanos Cancer Institute
2017 Phase 2 NCT03252600 United States;
Boston Medical Center
2008 Phase 2 NCT00679367 United States;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Heidelberg University
2009 Phase 2 NCT00883623 Germany;
Hellenic Oncology Cooperative Group
2007 - EUCTR2006-007082-36-GR Greece;
IRCCS Policlinico S. Matteo
2008 Phase 2 NCT00607581 Italy;
Mayo Clinic
2007 Phase 2 NCT00564889 United States;
PETHEMA Foundation
2010 Phase 2 NCT01194791 Spain;
Seoul National University Hospital
2019 Phase 3 NCT04298372 Korea, Republic of;
Stanford University
2009 - NCT00890552 United States;
Vaishali Sanchorawala
2004 Phase 2 NCT00091260 United States;
Lenalidomide, Dexamethasone and Cyclophosphamide
University of Athens
2008 Phase 1/Phase 2 NCT00981708 Greece;
Lenogastrim
Joint UCLH and UCL Biomedical Research Unit
2007 Phase 2;Phase 3 EUCTR2006-006395-37-GB United Kingdom;
Management of therapy complications
City of Hope Medical Center
2010 - NCT01199562 United States;
Melflufen
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Melphalan
Barbara Ann Karmanos Cancer Institute
2007 Phase 2 NCT00520767 United States;
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
2009 Phase 2 NCT01083316 United States;
2008 Phase 2 NCT00790647 United States;
2008 Phase 2 NCT00679367 United States;
2001 Phase 2 NCT00075608 United States;
2000 Phase 2 NCT00075621 United States;
E.M.N. - EUROPEAN MYELOMA NETWORK
2011 Phase 3 EUCTR2010-022395-31-DK Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;
2011 - EUCTR2010-022395-31-SE Denmark;Greece;Italy;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-022395-31-IT Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
2011 Phase 1,2 JPRN-UMIN000006604 Japan;
M.D. Anderson Cancer Center
2014 Phase 1 NCT01807286 United States;
Mayo Clinic
2005 Phase 3 NCT00477971 United States;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
Nanjing University School of Medicine
2007 Phase 3 NCT01998503 China;
National Cancer Institute (NCI)
2010 Phase 3 NCT01078454 United States;
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Stanford University
2009 - NCT00890552 United States;
University Hospital, Limoges
2000 Phase 3 NCT00344526 France;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Melphalan fulfenamide hydrochloride
ONCOPEPTIDES AB
2019 Phase 1;Phase 2 EUCTR2018-002761-19-IT Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Oncopeptides AB
2020 Phase 2 EUCTR2018-002761-19-DE Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2 EUCTR2018-002761-19-ES Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-PL Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-NO Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-GR Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002761-19-CZ Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Melphalan, thalidomide and dexamethasone
FDA Office of Orphan Products Development
2002 Phase 2 NCT01527032 -
Melphalan-Flufenamide (Melflufen)
Oncopeptides AB
2020 Phase 1/Phase 2 NCT04115956 Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
Miridesap
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000276-23-GB United Kingdom;United States;
Mycophenolate mofetil
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium
FoldRx Pharmaceuticals Limited
2009 - EUCTR2008-001262-87-DE France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-SE France;Germany;Portugal;Sweden;
2007 - EUCTR2006-002792-41-DE Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-SE Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Inc.
2008 Phase 2;Phase 3 EUCTR2008-001262-87-FR France;Germany;Portugal;Sweden;
2008 - EUCTR2008-001262-87-PT France;Germany;Portugal;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-002792-41-GB Germany;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002792-41-PT Germany;Portugal;Spain;Sweden;United Kingdom;
FoldRx Pharmaceuticals, Ltd.
2009 - EUCTR2009-011535-12-FR France;Germany;Italy;Portugal;Sweden;
NEOD001
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2017 Phase 2 EUCTR2016-000489-50-IT Italy;
Prothena Therapeutics Limited
2018 Phase 2 EUCTR2016-004664-18-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GR Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-ES Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004664-18-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-GB Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-ES Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-DE Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004318-14-AT Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
Prothena Therapeutics Ltd.
2017 Phase 2 NCT03154047 Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 NCT02632786 Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
2016 Phase 2 NCT02613182 United States;
2015 Phase 3 NCT02312206 Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
NTLA-2001
Intellia Therapeutics
2020 Phase 1 NCT04601051 New Zealand;Sweden;United Kingdom;
Neupogen
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
Oral drops solution
E.M.N. - EUROPEAN MYELOMA NETWORK
2012 - EUCTR2010-022395-31-ES Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
PEGYLATED RECOMBINANT HUMAN HYALURONIDASE PH20
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
PF-06291826-83/Fx-1006A
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Paracetamolo Zentiva Italia
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
Peripheral blood stem cell transplantation
Eastern Cooperative Oncology Group
2003 Phase 1 NCT00052884 United States;
1998 Phase 2 NCT00003353 United States;
Fred Hutchinson Cancer Research Center
2000 Phase 1/Phase 2 NCT00006251 Germany;Italy;United States;
2000 - NCT00014235 Germany;Italy;United States;
1999 - NCT00112593 United States;
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
Pomalidomide
Barbara Ann Karmanos Cancer Institute
2013 Phase 1 NCT01728259 Canada;New Zealand;United States;
Boston Medical Center
2012 Phase 1/Phase 2 NCT01570387 United States;
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
2021 Phase 2 EUCTR2019-001962-13-IT Italy;
M.D. Anderson Cancer Center
2014 Phase 1 NCT01807286 United States;
OSPEDALE POLICLINICO S. MATTEO
2012 - EUCTR2011-001787-22-IT Italy;
Weill Medical College of Cornell University
2021 Phase 2 NCT04270175 United States;
Pomalidomide and Dexamethasone
IRCCS Policlinico S. Matteo
2012 Phase 2 NCT01510613 Italy;
Propylene Glycol-Free Melphalan Hydrochloride
Boston Medical Center
2018 Phase 2 NCT02994784 United States;
Psyllium
Centre Hospitalier Universitaire de Nice
2021 - NCT04695340 France;
Quality-of-life assessment
Barbara Ann Karmanos Cancer Institute
2007 Phase 2 NCT00520767 United States;
RNA analysis
City of Hope Medical Center
2010 - NCT01199562 United States;
Recombinant interferon alfa
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Southwest Oncology Group
1996 Phase 2 NCT00002849 United States;
Revlimid
GMIHO mbH
2008 - EUCTR2008-001405-41-DE Germany;
OSPEDALE POLICLINICO S. MATTEO
2008 - EUCTR2007-006037-13-IT Italy;
Revusiran
Alnylam Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2015-005333-49-GB Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-SE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-DE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003835-20-BE Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2014-003835-20-GB Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
SOM0226
SOM Biotech SL
2014 Phase 1/Phase 2 NCT02191826 Spain;
STI-6129
Sorrento Therapeutics, Inc.
2021 Phase 1 NCT04316442 United States;
Sargramostim
Herbert Irving Comprehensive Cancer Center
1999 Phase 2 NCT00007995 United States;
Selinexor
Weill Medical College of Cornell University
2022 Early Phase 1 NCT04984330 United States;
Siltuximab
Memorial Sloan Kettering Cancer Center
2017 Phase 2 NCT03315026 United States;
Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
University of Tennessee
2008 Phase 1 NCT01815086 United States;
Standard of care therapy
IRCCS Policlinico S. Matteo
2019 Phase 2/Phase 3 NCT03474458 Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom;
Stem Cell Collection
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
Stem Cell Infusion
Boston Medical Center
2008 Phase 2 NCT00790647 United States;
Stem cell infusion
Boston Medical Center
2015 Phase 3 NCT02489500 United States;
2001 Phase 2 NCT00075608 United States;
Sunitinib malate
National Cancer Institute (NCI)
2009 Phase 1 NCT00890747 United States;
Tafamidis
Pfizer
2011 Phase 3 NCT01435655 Japan;
Tafamidis Meglumine 20mg Soft Gelatin Capsule (Clinical trial image)
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Tafamidis Meglumine 20mg Soft Gelatin Capsule (Commerical image)
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Tafamidis meglumine
Pfizer Inc.
2009 - EUCTR2009-011535-12-PT Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
2009 - EUCTR2009-011535-12-DE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Pfizer Japan Inc.
2011 Phase 3 JPRN-JapicCTI-111678 -
Tafamidis meglumine 20 mg soft gelatin capsules
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Tasmar
SOM Innovation Biotech SL (SOM Biotech)
2014 - EUCTR2014-001586-27-ES Spain;
Thalidomide
Guangdong General Hospital
2017 - ChiCTR-IPR-17012637 China;
Guangdong Provincial People's Hospital
2020 Phase 4 NCT04612582 China;
Memorial Sloan Kettering Cancer Center.
2002 Phase 2 NCT00089167 United States;
People's Hospital, Beijing University
2016 - ChiCTR-IPR-16008422 China;
Southwest Oncology Group
2004 Phase 2 NCT00064337 United States;
University College, London
2015 Phase 1/Phase 2 NCT02545907 United Kingdom;
Yogesh Jethava
2013 Phase 2 NCT01849783 United States;
Thiotepa
Roswell Park Cancer Institute
2006 - NCT00536601 United States;
VELCADE*1FL 3,
JANSSEN-CILAG
2005 - EUCTR2004-004871-12-IT Italy;
Valganciclovir
City of Hope Medical Center
2010 - NCT01199562 United States;
Velcade
European Myeloma Network
2020 Phase 2 EUCTR2018-004333-33-FR France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-NL France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-IT France;Greece;Italy;Netherlands;
2019 Phase 2 EUCTR2018-004333-33-GR France;Greece;Italy;Netherlands;
2012 Phase 3 EUCTR2010-022395-31-DE Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
HOVON Foundation
2012 Phase 3 EUCTR2010-021445-42-DE Belgium;Germany;Netherlands;
2012 Phase 2 EUCTR2010-021445-42-BE Belgium;Germany;Netherlands;
2011 Phase 2 EUCTR2010-021445-42-NL Belgium;Germany;Netherlands;
University College London
2010 - EUCTR2009-014906-33-GB United Kingdom;
Venetoclax
National Cancer Institute (NCI)
2021 Phase 1 NCT04847453 United States;
Tufts Medical Center
2017 Phase 1 NCT03000660 United States;
Vyndaqel 20mg soft capsule
Pfizer Inc.
2009 - EUCTR2009-011535-12-SE Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States;
Yttrium-90 radiolabelled anti-CD66 antibody
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
Yttrium90 radiolabelled antiCD66
University Southampton Hospital NHS Foundation Trust
2015 - EUCTR2015-002231-18-GB United Kingdom;
ZN-d5
K-Group Alpha, Inc.
2021 Phase 1/Phase 2 NCT05199337 United States;
Zirtec
Prothena Biosciences Limited
2022 Phase 3 EUCTR2021-000037-14-IT Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States;
[18F]Florbetaben
IRCCS Policlinico S. Matteo
2020 - NCT04392960 Italy;
[18F]florbetaben
Life Molecular Imaging GmbH
2022 Phase 3 NCT05184088 -
microarray analysis
Barbara Ann Karmanos Cancer Institute
2007 Phase 2 NCT00520767 United States;
polymerase chain reaction
City of Hope Medical Center
2010 - NCT01199562 United States;
protein expression analysis
City of Hope Medical Center
2010 - NCT01199562 United States;